Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW, Uetrecht JP, Miller ED, Pehlivanov ND, Haque SA, Harrison MJ, Kullak-Ublick GA, Li H, Patel NN, Patwardhan M, Price KD, Watkins PB, Chalasani NP.
Regev A, et al. Among authors: avigan mi.
J Autoimmun. 2020 Nov;114:102514. doi: 10.1016/j.jaut.2020.102514. Epub 2020 Aug 5.
J Autoimmun. 2020.
PMID: 32768244
Free article.
Review.